Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAXBiotechnology
+$0.00 today
- Market cap
- $622.71M
- Beta
- -0.53
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$2.59
Volume 1.30M
Average 0.54M
BCAX Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Bicara Therapeutics Inc. Common StockNASDAQ: BCAX
Retained Earnings · Q1 FY2026 · quarter ended Mar 2026
Retained earnings remains negative
Q1 FY2026 retained earnings was -$415.18M, compared with -$257.86M a year earlier.
Context
- Retained earnings amounted to 75.0% of total assets at the end of Q1 FY2026, up 21.1 pp from a year earlier.
- Retained earnings grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps falling in the next quarterly balance sheet after a -61.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (358.97M) USD
- Year-over-year change
- -62.4%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (358.97M) | -62.4% |
| FY2024 | 2024-12-31 | (221.02M) | -44.4% |
| FY2023 | 2023-12-31 | (153.02M) | -51.5% |
| FY2022 | 2022-12-31 | (101.04M) | — |
Retained Earnings vs competitors
How BCAX compares with its peers on the latest reported figures
- BCAX's Mar 2026 retained earnings of -$415.18M is the 3rd highest of the 6 companies compared; the peer median is -$449.49M.
- Its year-over-year change of -61.0% is the lowest of 6, against a peer median of -17.9%.
- Retained earnings amounts to 75.0% of total assets for BCAX, versus a peer median of 219.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | -$139.58M | -40.5% | — | 237.1% | |
| Mar 2026 | -$195.09M | +60.7% | — | 98.0% | |
BCAXBicara Therapeutics Inc. Common Stock | Mar 2026 | -$415.18M | -61.0% | — | 75.0% |
| Mar 2026 | -$449.49M | -17.9% | — | 219.1% | |
| Mar 2026 | -$637.78M | -53.0% | — | 158.3% | |
| Mar 2026 | -$1.28B | -5.8% | — | 588.0% | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding BCAX) | -$449.49M | -17.9% | — | 219.1% | |
Competitors are the stored peer set for BCAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
Intrinsic Alpha fair value
Locked
Current Price
$9.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.